Navigation Links
BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center
Date:4/30/2008

ability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
2. Cord Blood America in Top 20 in Los Angeles Area Biotech-Biomed Companies
3. BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
4. BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock
5. BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors
6. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
7. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
8. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
9. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
10. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
11. LifeNet Health(R) Unveils New Biomedical Spine Implant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... LANSING, Mich., July 22, 2014  Neogen Corporation (NASDAQ: ... its 2014 fiscal year, which ended May 31, increased ... net income was $28,158,000, compared to the prior year,s ... 30, 2013, earnings per share in the current year ... revenues and net income for the 2014 fiscal year ...
(Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... July 22, 2014  United Therapeutics Corporation (NASDAQ: ... will release its second quarter 2014 financial results ... United Therapeutics will host a half-hour ... a.m. Eastern Time.  The teleconference is accessible by ... rebroadcast of the teleconference will be available for ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Williams ... those who have recognized that the greatest health care ... far too often needlessly deadly while trying to serve ... of quasi-experts seeking to transform an enormous system that ... Dr. Williams, in his continuing series of Open Letters ...
Breaking Biology Technology:Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
... in Key Markets, Differentiated Product Offerings and ... Performance, CARY, N.C., Jan. 10 ... significant milestone with the signing of its ... additional customers during the,second half of 2007. ...
... LONDON, January 10 Amarin Corporation plc,(NASDAQ: AMRN ... and ethical approvals to commence a Phase IIa trial ... The Phase IIa trial will be a randomized, ... AAMI who,will be randomized to receive 1, 2 or ...
... Essilor International,s US subsidiary, has strengthened its,prescription laboratory ... Interstate Optical Co., one of the country,s five ... and,Indianapolis, Indiana serve eye care professionals in 32 ... and 210 employees., Present for more than ...
Cached Biology Technology:SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 2SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 3SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 4Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 2Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 3Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 4
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST), ... dramatically improved technique for analyzing biological cells and ... new NIST technique is an advanced form of ... that delivers signals that are 10,000 times stronger ... times stronger than obtained from comparable "coherent Raman" ...
(Date:7/22/2014)... N.C. In a cost-effectiveness analysis of commercial diet ... drug Qsymia showed the best value for the money. ... but was also the most expensive option tested, according ... Medical School. , The findings, published in the June ... information on the health and weight-loss benefits per dollar ...
(Date:7/22/2014)... Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor of ... Orleans School of Nursing, contributed samples used in ... associated with schizophrenia and also suggesting a possible ... study, Biological insights from 108 schizophrenia-associated genetic loci, ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
... In order for medical students to ultimately provide quality patient ... teach physiology, one of the core disciplines of medicine, according ... Journal of the American College of Radiology ( www.jacr.org ... systems. "It is vital that medical schools provide ...
... Avantra Biosciences (Avantra) today announced the selection ... test site for Avantra,s new biomarker quantitation platform. ... has created an automated multiplex immunoassay system to ... patient characteristics, and drug responses. The new Q400 ...
Cached Biology News:Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Avantra Biosciences teams with TGen Drug Development to assist pharma 2
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
... (patent pending) was developed using a protein engineering ... DNA binding pocket of wild-type DNase I. These ... for DNA. The result is a versatile enzyme ... and an ability to maintain at least 50% ...
Request Info...
Biology Products: